Merus to Present at BofA Securities 2025 Health Care Conference
Merus (Nasdaq: MRUS), a biotechnology company specializing in oncology and the development of multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Bill Lundberg will engage in a fireside chat on May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. The presentation will be available via webcast on the company's Investors webpage, with a recording accessible for a limited time afterward.
Merus (Nasdaq: MRUS), un'azienda biotecnologica specializzata in oncologia e nello sviluppo di anticorpi multispecifici (Biclonics® e Triclonics®), ha annunciato la sua partecipazione alla BofA Securities 2025 Health Care Conference. Il CEO Bill Lundberg parteciperà a una conversazione informale il 15 maggio 2025, alle 8:40 PT/11:40 ET. La presentazione sarà disponibile in webcast sulla pagina Investitori della società, con una registrazione accessibile per un periodo limitato successivamente.
Merus (Nasdaq: MRUS), una empresa biotecnológica especializada en oncología y en el desarrollo de anticuerpos multispecíficos (Biclonics® y Triclonics®), ha anunciado su participación en la BofA Securities 2025 Health Care Conference. El CEO Bill Lundberg participará en una charla informal el 15 de mayo de 2025, a las 8:40 a.m. PT/11:40 a.m. ET. La presentación estará disponible vía webcast en la página de Inversores de la compañía, con una grabación accesible por tiempo limitado después.
Merus (나스닥: MRUS)는 종양학 및 다중특이성 항체(Biclonics® 및 Triclonics®) 개발을 전문으로 하는 바이오테크 기업으로, BofA Securities 2025 Health Care Conference에 참여할 예정입니다. CEO 빌 런드버그는 2025년 5월 15일 오전 8시 40분 PT/오전 11시 40분 ET에 파이어사이드 채팅에 참석합니다. 발표 내용은 회사 투자자 웹페이지를 통해 웹캐스트로 제공되며, 이후 일정 기간 동안 녹화본도 이용할 수 있습니다.
Merus (Nasdaq : MRUS), une société de biotechnologie spécialisée en oncologie et dans le développement d’anticorps multispecifics (Biclonics® et Triclonics®), a annoncé sa participation à la BofA Securities 2025 Health Care Conference. Le PDG Bill Lundberg participera à une discussion informelle le 15 mai 2025 à 8h40 PT/11h40 ET. La présentation sera disponible en webcast sur la page Investisseurs de la société, avec un enregistrement accessible pour une durée limitée par la suite.
Merus (Nasdaq: MRUS), ein Biotechnologieunternehmen, das sich auf Onkologie und die Entwicklung multispezifischer Antikörper (Biclonics® und Triclonics®) spezialisiert hat, hat seine Teilnahme an der BofA Securities 2025 Health Care Conference angekündigt. CEO Bill Lundberg wird am 15. Mai 2025 um 8:40 Uhr PT/11:40 Uhr ET an einem Fireside Chat teilnehmen. Die Präsentation wird per Webcast auf der Investorenseite des Unternehmens verfügbar sein, mit einer Aufzeichnung, die anschließend zeitlich begrenzt abrufbar ist.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. Director IR/Corp Comms 617-230-4165 k.farren@merus.nl
FAQ
When is Merus (MRUS) presenting at the BofA Securities 2025 Health Care Conference?
Who will represent Merus (MRUS) at the BofA Securities 2025 Healthcare Conference?
How can investors access Merus's (MRUS) presentation at the BofA Securities conference?
What type of antibody technology does Merus (MRUS) develop?
